ReviewGut microbes
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
Review in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health.World journal of gastroenterology · 2026Pooled it
- Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis.Liver international : official journal of the International Association for the Study of the Liver · 2025Pooled it
- Global research trends in bacteriophage and gut microbiota: a bibliometric and visual analysis from 2012 to 2025.Frontiers in microbiology · 2025Pooled it
- Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study.Frontiers in nutrition · 2025Pooled it
- Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2024Pooled it
- Trial
- Bile salt hydrolase activity as a rational target for MASLD therapy.Gut microbes · 2026Article
- Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation.Gut microbes · 2026Article
- Underlying MASLD-induced gut microbiome dysbiosis and intestinal inflammation are key to poor outcomes in vibriosis infections in a preclinical model.Gut microbes · 2026Article
- Bariatric surgery may alleviate MASLD by restoring mitochondria-lipid droplet structural and functional integrity through suppression of the Mitochondrial Fission Factor-Perilipin 5 axis.Molecular biomedicine · 2026Article
- MetALD Molecular Signatures: What We Know, What We Lack, and How to Move Forward Through Integrated Multi-Omics.Metabolites · 2026Review
- Article
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
- Article
- Metabolic and Lifestyle Profiles of Metabolic Dysfunction-Associated Steatotic Liver Disease in Romanian and Italian Adults.Medicina (Kaunas, Lithuania) · 2026Observational
- Exercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle-Gut-Thyroid Axes in MASLD/MASH.International journal of molecular sciences · 2026Review
- Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications.BMJ open gastroenterology · 2026Review
- Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice.Nature microbiology · 2026Article
- Periodontitis aggravates high-fat diet-induced MASLD via gut microbiota dysbiosis and metabolic dysfunction in mice.Scientific reports · 2026Article
- Sodium Humate Combined with Low-Dose Cefixime Alleviates Intestinal Injury in ETEC Infection via Inhibition of the TLR4/NF-κB Pathway.Biomolecules · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity, insulin resistance (IR), and the gut microbiome intricately interplay in Metabolic-associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), a growing health concern. The complex progression of MASLD extends beyond the liver, driven by "gut-liver axis," where diet, genetics, and gut-liver interactions influence disease development. The pathophysiology of MASLD involves excessive liver fat accumulation, hepatocyte dysfunction, inflammation, and fibrosis, with subsequent risk of hepatocellular carcinoma (HCC). The gut, a tripartite barrier, with mechanical, immune, and microbial components, engages in a constant communication with the liver. Recent evidence links dysbiosis and disrupted barriers to systemic inflammation and disease progression. Toll-like receptors (TLRs) mediate immunological crosstalk between the gut and liver, recognizing microbial structures and triggering immune responses. The "multiple hit model" of MASLD development involves factors like fat accumulation, insulin resistance, gut dysbiosis, and genetics/environmental elements disrupting the gut-liver axis, leading to impaired intestinal barrier function and increased gut permeability. Clinical management strategies encompass dietary interventions, physical exercise, pharmacotherapy targeting bile acid (BA) metabolism, and microbiome modulation approaches through prebiotics, probiotics, symbiotics, and fecal microbiota transplantation (FMT). This review underscores the complex interactions between diet, metabolism, microbiome, and their impact on MASLD pathophysiology and therapeutic prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.